Advertisement

Related Videos

Welcome and Introduction to Vi3C

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement




Jun
21
Today In Oncology
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
AGA Recommends Colonoscopy Over Alternative Colorectal Cancer Screening Methods
AI-Assisted Tumor Volume Response Criteria Outperform Physician Assessments and RECIST Criteria in Pleural Mesothelioma
Overall Survival With EBRT in Hepatocellular Carcinoma
HCC TACE Plus STRIDE With or Without Lenvatinib
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo